Supporting the use of CSF biomarkers for early diagnosis, decreased Aβ42 and increased T-tau and P-tau are seen in patients with mild cognitive impairment (MCI) later diagnosed with AD. This evidence concerns the gene MAPT and Alzheimer disease.